title: Current concepts in the diagnosis and management of small-cell lung cancer.
abstract: Despite a decreasing incidence in the United States, small-cell lung cancer (SCLC) remains a major clinical problem, with approximately 30,000 new cases each year. The diagnosis of SCLC is usually not difficult. The Veterans Administration Lung Study Group (VALSG) staging system is less accurate than the American Joint Committee of Cancer tumor-node-metastasis (TNM) system (7th edition) at predicting survival in SCLC, especially in lower stage disease. Surgery has not played a major part in the management of SCLC, but emerging data suggest that resection may have a role in earlier stage disease. While the frontline treatment of SCLC has not changed significantly in the past decade, newer agents that are currently being investigated provide hope for better treatment of relapsed/refractory disease for the future.
authors.affiliation: Department of Internal Medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska 68198-7680, USA. aganti@unmc.edu
authors.forename: Apar Kishor
authors.initials: AK
authors.lastname: Ganti
authors.forename: William W
authors.initials: WW
authors.lastname: West
authors.forename: Rudy P
authors.initials: RP
authors.lastname: Lackner
authors.forename: Anne
authors.initials: A
authors.lastname: Kessinger
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D043823:Taxoids / Q000008:administration & dosage; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use
chemical_list: D018943:Anthracyclines; D043823:Taxoids; D059004:Topoisomerase I Inhibitors; C055866:amrubicin